ACE2 News and Research

RSS

Novel hydrogel-based vaccine formulation shows high efficacy against SARS-CoV-2

A fascinating new preprint research paper posted to the bioRxiv* server discusses impressively high neutralizing responses elicited with a single dose of a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine formulation, which could help turn the tide of the current pandemic if validated.

6 Apr 2021

Research explores sex differences in placental defenses against SARS-CoV-2 infection

A plethora of earlier studies has reported on the differences between the sexes in susceptibility to the currently circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as well as its severity. A new preprint research paper posted to the bioRxiv* server extends this to the placenta in pregnancy.

6 Apr 2021

South Africa SARS-CoV-2 variant B.1.351 easily escapes Sputnik vaccine

A new preprint research paper posted to the medRxiv* server reports on vaccine resistance data that pushes the end of the pandemic further away.

6 Apr 2021

New nanoparticle SARS-CoV-2 vaccine confers robust protection with single dose after two weeks

In a methodologically ‘state-of-the-art’ approach, US researchers have developed a protein-based nanoparticle vaccine against coronavirus disease (COVID-19), with a swift generation of antibodies and the potential to protect individuals who cannot receive other COVID-19 vaccines for medical reasons. The research is posted to the bioRxiv* preprint server.

5 Apr 2021

Researchers Identify potent small molecule inhibitors against SARS-CoV-2

A team of scientists from the USA and Sweden has recently screened 8 million small molecule inhibitors against SARS-CoV-2.

5 Apr 2021

The use of mammalian cell surface display for rapid characterization of SARS-CoV-2 variants

A research group from the U.S. demonstrated the practicality of a spike display system in order to accelerate vaccine design, but also to swiftly appraise the effects of mutations in emerging strains of the SARS-CoV-2.

5 Apr 2021

Chemical inhibitor can reduce SARS-CoV-2's ability to infect host cell lines

James McKerrow, MD, PhD, dean of the Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego, has long studied neglected tropical diseases -- chronic and disabling parasitic infections that primarily affect poor and underserved communities in developing nations.

3 Apr 2021

Study discovers new target on SARS-CoV-2 spike for protective antibodies

Researchers at The Scripps Research Institute, USA, have described a potential target for COVID-19 vaccines. Dubbed as CC40.8 bnAb, it exhibited broad reactivity with human beta coronaviruses.

1 Apr 2021

Glycans influence SARS-CoV-2 spike–ACE2 binding affinity, finds study

A study conducted at the Los Alamos National Laboratory, USA, and Concordia University, Canada, has explored the impact of different types of glycans on the interaction between SARS-CoV-2 spike protein and human ACE2 receptor.

1 Apr 2021

Could a flavonoid found in common fruit and vegetables combat COVID-19?

Researchers in India have gathered and presented a large body of evidence highlight quercetin – a flavonoid molecule found in many common fruits and vegetables – may be developed into drug therapies used to combat COVID-19.

1 Apr 2021

Researchers develop a recombinant SARS-CoV-2 receptor-binding domain trimer vaccine candidate

New research deals with the development of RBD trimer as a potent target for SARS-CoV-2 subunit vaccines. This study revealed the development of a trimeric RBD subunit vaccine candidate that could induce strong humoral and cellular immune responses in nonhuman primates (NHPs), namely, rhesus macaques.

1 Apr 2021

Antibodies produced from infection with SARS-CoV-2 501Y.V2 protect against other variants

A recent paper in the journal Nature shows that while earlier lineages do not elicit antibodies capable of efficiently neutralizing the newly emerged South African variant, SARS-CoV-2 501Y.V2 (B.1.351), the converse does occur.

31 Mar 2021

Study estimates impact of amino acid changes on SARS-CoV-2 infection

New research led by Costas D. Maranas from The Pennsylvania State University predicts amino acid changes to the receptor-binding domain of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein would negatively impact binding affinity and subsequent infection into human cells.

31 Mar 2021

B.1.1.7 rapidly becoming the dominant SARS-CoV-2 variant in the United States

The faster-spreading B.1.1.7 variant of SARS-CoV-2 first detected in the United Kingdom, the coronavirus that causes COVID-19, is quickly on its way to becoming the dominant variant of the virus in the United States, according to a study from scientists at Scripps Research and the COVID-19 test maker Helix.

31 Mar 2021

New mRNA COVID-19 vaccine candidate shows promise in vivo

Researchers report that a new lipid nanoparticle mRNA coronavirus disease 2019 (COVID-19) vaccine candidate protected 70% of mice expressing the human angiotensin-converting enzyme 2 (ACE2), while all the non-vaccinated mice died.

31 Mar 2021

Are marine mammals are at risk of COVID-19?

Researchers have identified a number of marine mammal species native to Italian seawaters that may be highly susceptible to the disease. Additionally, these species inhabit ocean areas where the virus may be present even after receiving sewage treatment, thus highlighting the need for strict sewage improvement plans.

31 Mar 2021

Researchers evaluate antibodies that inhibit SARS-CoV-2 RBD variants with a novel assay

A team of researchers recently discussed the potential role of a new assay in bridging a major gap in SARS-CoV-2 research. This assay can throw light on 1) the selection of complementary monoclonal antibody candidates and 2) rapid identification of the immune escape to emerging RBD variants following vaccination or natural infection.

31 Mar 2021

Obesity and ethnicity identified as key risk factors for SARS-CoV-2 exposure in UK

The risk factors for severe COVID-19 have been established on the basis of observational studies. However, SARS-CoV-2 continues to cause thousands of COVID-19 cases all over the world, and the risk factors are unclear. A new study deals with this aspect of the pandemic.

31 Mar 2021

Development of a model of substrate coordination to Zn-bound ACE2

The ongoing coronavirus disease-19 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has claimed more than 2.8 million lives worldwide. Authorities are facing difficulty in preventing the spread of disease due to the highly infectious nature of SARS-CoV-2. Therefore, reducing the virus's ability to infect an individual's respiratory epithelial cells could prove an effective measure to prevent disease transmission.

31 Mar 2021

SARS-CoV-2 mutation T478K spreading at alarming speed in Mexico

Several SARS-CoV-2 variants have emerged, posing a renewed threat to COVID-19 containment and to vaccine and drug efficacy. In this study, we analyzed more than 820,000 SARS-CoV-2 genomic sequences deposited up to March 26, 2021 and identified a novel T478K mutation located on the SARS-CoV-2 Spike protein.

30 Mar 2021